Cite
HARVARD Citation
Essink, B. et al. (n.d.). 3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older. Open forum infectious diseases. p. S2. [Online].